Rep. Rick W. Allen Sells Shares of Abbott Laboratories (NYSE:ABT)

Key Points

• Rep. Rick W. Allen sold $15,001–$50,000 of Abbott Laboratories shares on July 14, while purchasing shares of Broadcom and Advanced Micro Devices.
• Abbott reported quarterly EPS of $1.31, exceeding estimates, with revenue up 13% year over year to $12.59 billion. The company also paid a quarterly dividend of $0.63 per share, while analysts maintain a “Moderate Buy” consensus rating.
• Abbott is expanding its diabetes and diagnostic businesses through new distribution partnerships, but agreed to pay approximately $670 million to settle part of its premature-infant formula litigation; additional claims remain unresolved.

Representative Rick W. Allen (Republican-Georgia) recently sold shares of Abbott Laboratories NYSE: ABT. In a filing disclosed on August 18th, the Representative disclosed that they had sold between $15,001 and $50,000 in Abbott Laboratories stock on July 14th. The trade occurred in the Representative's "LIVTR" account.

Representative Rick W. Allen also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of Broadcom NASDAQ: AVGO on 7/14/2026.
• Purchased $1,001 - $15,000 in shares of Advanced Micro Devices NASDAQ: AMD on 7/14/2026.
• Sold $15,001 - $50,000 in shares of Intuit NASDAQ: INTU on 6/10/2026.

Abbott Laboratories Price Performance

Shares of ABT stock opened at $116.62 on Friday. The firm's 50 day moving average price is $100.08 and its two-hundred day moving average price is $100.05. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38. Abbott Laboratories has a 52-week low of $81.97 and a 52-week high of $137.49. The stock has a market cap of $201.80 billion, a PE ratio of 37.74, a PEG ratio of 2.21 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, beating the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The company had revenue of $12.59 billion during the quarter, compared to analysts' expectations of $12.52 billion. During the same quarter in the previous year, the company posted $1.26 EPS. The business's revenue for the quarter was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, analysts forecast that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 17th. Investors of record on Wednesday, July 15th were issued a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 2.2%. The ex-dividend date was Wednesday, July 15th. Abbott Laboratories's dividend payout ratio is currently 81.55%.

Analyst Ratings Changes

ABT has been the subject of a number of recent analyst reports. Bank of America lowered their price target on Abbott Laboratories from $120.00 to $102.00 in a research note on Friday, June 12th. Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $130.00 target price on shares of Abbott Laboratories in a research note on Friday, July 17th. BTIG Research boosted their price target on shares of Abbott Laboratories from $131.00 to $134.00 and gave the company a "buy" rating in a report on Friday, July 17th. Citigroup raised their price objective on Abbott Laboratories from $108.00 to $112.00 and gave the stock a "buy" rating in a research note on Friday, July 17th. Finally, Weiss Ratings upgraded Abbott Laboratories from a "sell (d+)" rating to a "hold (c-)" rating in a report on Thursday, August 6th. Three research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, Abbott Laboratories presently has an average rating of "Moderate Buy" and a consensus price target of $118.67.

Hedge Funds Weigh In On Abbott Laboratories

Several hedge funds have recently made changes to their positions in the business. Cornerstone Financial Management LLC acquired a new stake in Abbott Laboratories in the 4th quarter valued at $25,000. MidAtlantic Capital Management Inc. acquired a new position in shares of Abbott Laboratories during the 4th quarter worth about $25,000. Purpose Unlimited Inc. bought a new position in shares of Abbott Laboratories in the 4th quarter valued at about $25,000. Portfolio Resources Advisor Group Inc. acquired a new stake in shares of Abbott Laboratories in the fourth quarter valued at about $26,000. Finally, Abound Financial LLC bought a new stake in Abbott Laboratories during the fourth quarter worth about $26,000. 75.18% of the stock is owned by institutional investors.

Abbott Laboratories News Roundup

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott’s Instinct continuous glucose sensor is now commercially shipping in the U.S. integrated with MiniMed’s Flex automated insulin-delivery system. The partnership expands Abbott’s presence in diabetes technology and could support sensor adoption and recurring revenue. MiniMed Ships MiniMed Flex With Abbott's Smallest Instinct Sensor
• Positive Sentiment: Abbott also entered a multiyear agreement with HealthTab to distribute its Afinion 2 point-of-care analyzers through NHS-linked pharmacies in the United Kingdom. The deal may broaden access to Abbott’s HbA1c and lipid-testing products, although financial details were not disclosed. HealthTab Enters Multi-Year Collaboration Agreement with Abbott
• Neutral Sentiment: Abbott agreed to pay approximately $670 million to resolve the Gill case and claims from roughly 2,000 individuals involving specialty formulas for premature infants. The settlement resolves a portion of the litigation, including the appeal of a prior $495 million verdict, reducing uncertainty and potentially avoiding additional legal costs. Abbott denied that its products cause necrotizing enterocolitis and said regulators and medical professionals consider the formulas safe and necessary. Abbott agrees to $670 million settlement of infant formula cases
• Negative Sentiment: The settlement represents a significant cash and earnings cost and does not resolve all potential litigation related to the infant formulas. Investors may continue to assess the scope of remaining claims and the effect on Abbott’s legal reserves and profitability. Abbott reaches agreements to resolve a portion of litigation involving its specialty formulas

About Representative Allen

Rick Allen (Republican Party) is a member of the U.S. House, representing Georgia's 12th Congressional District. He assumed office on January 3, 2015. His current term ends on January 3, 2027. Allen (Republican Party) ran for re-election to the U.S. House to represent Georgia's 12th Congressional District. He won in the general election on November 5, 2024. Allen was born in Augusta, Georgia, in 1951. He attended Auburn University in Alabama, graduating in 1973 with a B.S. in building construction. After earning his degree, Allen worked as an estimator, project administrator and assistant to the president with a construction firm in Augusta. In 1976, he founded his own construction business, R. W. Allen & Associates, Inc. The company operates in six states across the country. In 2008, Allen was presented with the Augusta Metro Chamber of Commerce’s Small Business Person of the Year award.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source